HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer

Radiotherapy and Oncology

Volumn 94, Issue 1, 2010, Pages 30-35

  Lassen, Pernille ^a   Eriksen, Jesper Grau ^a   Hamilton Dutoit, Stephen ^a   Tramm, Trine ^a   Alsner, Jan ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

HNSCC; HPV; Hypoxia; p16; Radiotherapy

Indexed keywords

NIMORAZOLE; PLACEBO; PROTEIN P16;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTITRICHOMONAL AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIMORAZOLE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 74549123751     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.10.008     Document Type: Article

References (23)

1. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000) 709-720
2. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 (2007) 1944-1956
3. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100 (2008) 261-269
4. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24 (2006) 5630-5636
5. Weinberger P.M., Yu Z., Haffty B.G., et al. Molecular classification identifies a subset of human papillomavirus - associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24 (2006) 736-747
6. Kumar B., Cordell K.G., Lee J.S., et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26 (2008) 3128-3137
7. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., and Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 27 (2009) 1992-1998
8. Smeets S.J., Hesselink A.T., Speel E.J., et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121 (2007) 2465-2472
9. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 (2004) 198-206
10. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
11. Busk M., Horsman M.R., Jakobsen S., et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?. Radiother Oncol 92 (2009) 429-436
12. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
13. Nordsmark M., and Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 43 (2004) 396-403
14. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
15. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25 (2007) 4066-4074
16. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
17. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., and Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
18. Eriksen J.G., and Overgaard J. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol 83 (2007) 383-388
19. Nordsmark M., Eriksen J.G., Gebski V., Alsner J., Horsman M.R., and Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83 (2007) 389-397
20. Gillison M.L. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol 24 (2006) 5623-5625
21. Santa Cruz Biotechnology: Datasheet anti-p16 clone JC8. Available from: http://www.scbt.com/datasheet-56330-p16-jc8-antibody.html.
22. Baumann M., Krause M., and Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8 (2008) 545-554
23. Kreimer A.R., Clifford G.M., Boyle P., and Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 (2005) 467-475